candesartan
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypertrophic Cardiomyopathy
Conditions
Hypertrophic Cardiomyopathy
Trial Timeline
— → —
NCT ID
NCT00430833About candesartan
candesartan is a phase 2 stage product being developed by AstraZeneca for Hypertrophic Cardiomyopathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT00430833. Target conditions include Hypertrophic Cardiomyopathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00430833 | Phase 2 | UNKNOWN |
| NCT00679640 | Pre-clinical | Completed |
| NCT00320970 | Pre-clinical | Completed |
| NCT00252694 | Phase 3 | Completed |
| NCT00252720 | Phase 3 | Completed |
| NCT00130975 | Phase 3 | Completed |
| NCT00150631 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Hypertrophic Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mavacamten | LianBio | Phase 1 | 25 |
| Mavacamten + Placebo | LianBio | Phase 3 | 69 |
| CT-G20 + Placebo | Celltrion | Phase 1 | 33 |
| LCZ696 + Placebo | Novartis | Phase 2 | 52 |
| Eleclazine + Placebo | Gilead Sciences | Phase 2/3 | 64 |
| Ranolazine | Gilead Sciences | Approved | 84 |
| PF-06473871 + PF-06473871 | Pfizer | Phase 2 | 51 |
| PF-06473871 + PF-06473871 | Pfizer | Phase 2 | 51 |
| EXC 001 + EXC 001 + EXC 001 + EXC 001 | Pfizer | Phase 2 | 51 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Mavacamten + Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| MYK-224 | Bristol Myers Squibb | Phase 2 | 51 |
| mavacamten | Bristol Myers Squibb | Phase 2/3 | 64 |
| mavacamten | Bristol Myers Squibb | Phase 2 | 51 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten + Placebo | Bristol Myers Squibb | Phase 3 | 76 |